AMENDMENT NO.12 TO SHAREHOLDERS’ AGREEMENT OF KIRIN-AMGEN
Exhibit 10.49
AMENDMENT NO.12
TO SHAREHOLDERS’ AGREEMENT OF KIRIN-AMGEN
TO SHAREHOLDERS’ AGREEMENT OF KIRIN-AMGEN
AMENDMENT NO.12 (this “Amendment”) dated January 31, 2001, to the Shareholders’ Agreement of
Kirin-Amgen dated May 11, 1984 (as amended, the “Shareholders’ Agreement”) among Kirin Brewery Co.,
Ltd., a Japanese corporation with principal offices located at 00-0, Xxxxxxxx 0-xxxxx, Xxxx-xx,
Xxxxx, 000-0000, Xxxxx (“Kirin”), Amgen Inc., a Delaware corporation with principal offices located
at Xxx Xxxxx Xxxxxx Xxxxx, Xxxxxxxx Xxxx, Xxxxxxxxxx 00000 (“Amgen”) and Kirin-Amgen, Inc., a
Delaware corporation with principal offices located at x/x Xxxxx Xxxxxx XX, Xxxxxxxxx, 0000 Xxxxxx,
Xxxxxxxxxxx (“Kirin-Amgen”).
WITNESSETH:
WHEREAS, Kirin, Amgen and Kirin-Amgen entered into RESEARCH, DEVELOPMENT AND TECHNOLOGY
DISCLOSURE AGREEMENT: TPO/MGDF (hereinafter, the “Research Agreement”) and TPO/MGDF TECHNOLOGY
TRANSFER AGREEMENT, (hereinafter, the “Technology Agreement”; collectively these two agreements
shall be referred to as the “Agreements”) and Kirin and Amgen each entered into a TPO/MGDF LICENSE
AGREEMENT with Kirin-Amgen (hereinafter respective called the “Kirin License Agreement” and the
“Amgen License Agreement”), all these agreements dated December 9, 1994 and effective as of June
14, 1994.
WHEREAS, this Amendment sets forth certain agreement between the Parties with respect to the
manufacture, production and worldwide commercial sale of human diagnostics and reagents relating to
TPO/MGDF (as defined in the Agreements).
WHEREAS, this Amendment also sets forth certain agreement between the Parties with respect to
the prior arrangements implemented with respect to the sale of human diagnostics and reagents
relating to Epo and G-CSF.
NOW, THEREFORE, in consideration of the mutual covenants expressed herein and other good and
valuable consideration, the parties agree as follows:
| 1. | COMMERCIAL REAGENT: EXPANSION OF BUSINESS OPPORTUNITIES |
1.01 License to Kirin-Amgen. The Parties hereto agree that Kirin and Amgen each grant
Kirin-Amgen a royalty-free, exclusive and worldwide license to develop, make, have made, use, sell
and have sold human diagnostics and commercial reagents, including but not limited to a reagent,
kit or service using such reagent and/or kit, relating to TPO/MGDF (“TPO/MGDF Commercial Reagent”)
for uses not included within Human Pharmaceutical Use (as defined in the Agreements) and not included as veterinary or animal uses (the “Field of Use”). The Parties
agree that the right to develop, make, have made, use, sell and have sold TPO/MGDF Commercial
Reagent shall include the right to develop, make, have made, use, sell and have sold antibodies
-1-
relating to the TPO/MGDF to the extent required for use in TPO/MGDF Commercial Reagent within the
Field of Use.
1.02 License to Kirin and Amgen. The Parties hereto agree that Kirin-Amgen grants
Kirin and Amgen, respectively, a royalty-free, co-exclusive (with Amgen and Kirin only) and
worldwide license to develop, make, have made, use, sell and have sold the TPO/MGDF Commercial
Reagent in the Field of Use.
1.03 Territories. Amgen’s right granted by Kirin-Amgen under the Amgen License
Agreement shall be royalty-free, worldwide and co-exclusive with Kirin with respect to the TPO/MGDF
Commercial Reagent. Kirin’s right granted by Kirin-Amgen under the Kirin License Agreement shall
be royalty-free, worldwide and co-exclusive with Amgen with respect to the TPO/MGDF Commercial
Reagent.
| 2. | FIRST COMMERCIAL SALE |
The Parties hereto agree that the sale of TPO/MGDF Commercial Reagent shall not be considered
to be the First Commercial Sale (as defined in the Research Agreement). Except for the purpose of
the sale or promotion of the TPO/MGDF Commercial Reagent, neither Kirin nor Amgen shall provide
TPO/MGDF to third parties in any country outside of their respective territories (as defined as
“Kirin Territory” and “Amgen Territory” in the Agreements) without prior written consent of the
other party, prior to the First Commercial Sale of TPO/MGDF by the other party or its affiliates or
licensees in that country.
| 3. | CONSISTENCY WITH SHAREHOLDERS’ AGREEMENT; RATIFICATION |
3.01 Consistency. The rights and obligations of the Parties hereto with respect to
this Amendment No. 12 as an expansion of Kirin-Amgen’s business opportunities are otherwise
consistent with the Shareholders’ Agreement.
3.02 Ratification. All of the terms and conditions of the Shareholders’ Agreement as
amended by this Amendment No.12 are hereby ratified and confirmed in all respects.
| 4. | FURTHER INSTRUMENTS |
The Parties hereto agree to perform any and all further acts and execute and deliver any and
all further documents and/or instruments which may be reasonable or necessary to carry out the
provisions of this Amendment.
-2-
| 5. | RATIFICATION OF PAST ARRANGEMENTS WITH RESPECT TO HUMAN DIAGNOSTICS AND COMMERCIAL REAGENT SALES OF EPO AND G-CSF |
The parties agree and acknowledge and hereby formally ratify the following:
A. Effective as of January 1, 1991: Amgen shall have exclusive, royalty-free rights to sell
human diagnostics and commercial reagents of EPO throughout the world with the exception of Japan;
Kirin shall have the exclusive royalty-free rights to sell human diagnostics and commercial
reagents of EPO within Japan. Except as modified herein, the terms of such agreement are set forth
in Amendment No. 1 to the Shareholders’ Agreement and the relevant exhibits thereto.
B. Effective as of January 1, 1991: Amgen shall have exclusive, royalty-free rights to sell
human diagnostics and commercial reagents of G-CSF within the United States, Europe, Australia,
Canada and New Zealand; Kirin shall the exclusive royalty-free rights to sell human diagnostics and
commercial reagents of G-CSF within Japan, Korea, Taiwan and the PRC; Kirin and Amgen shall share
co-exclusive, royalty-free rights to sell human diagnostics and commercial reagents of G-CSF for
the rest of the world.
C. There will be no alteration, adjustment or correction in the past payment (or lack of
payment) of any royalty related to sales of commercial reagents or human diagnostics for EPO or
G-CSF by either Party prior to the execution of this document. The Parties ratify all previous
activity in the area of accounting for past sales.
D. Except as specifically set forth above, this subsection does not alter or amend any
existing agreement involving Kirin, Amgen and/or Kirin-Amgen with respect to human diagnostics
and/or commercial reagents.
IN WITNESS WHEREOF, the Parties hereto have caused this Amendment to be executed by their duly
authorized representatives in the manner legally binding on them.
| Kirin Brewery Co., Ltd. | Amgen Inc. | |||||||||||
| /s/ Xxxxxxxx Xxxxxxx | /s/ Xxxxx Xxxxxx | |||||||||||
By: Xxxxxxxx Xxxxxxx
|
By: Xxxxx Xxxxxx | |||||||||||
Title:
|
President, Pharmaceutical Division | Title: Vice President, APLA | ||||||||||
| Kirin-Amgen, Inc. | ||||||||||||
| /s/ Xxxxxxxxx Xxxxx | ||||||||||||
| By: Xxxxxxxxx Xxxxx, Ph.D. | ||||||||||||
| Title: Chairman | ||||||||||||
-3-
